| |SEPTEMBER 20268TOP STORIESINDIA'S PEPTIDE API RACE HEATS UP AS HRV PHARMA COMMITS 150 CROREOBESITY DRUG MARKET SWINGS BETWEEN BIG WINS AND BIGGER DOUBTSHOW CHRONIC CARE & GLP-1 THERAPEUTICS ARE RESHAPING THE IPMCENTRE'S HPV DRIVE UNDER WATCH AS PIL SEEKS SUPREME COURT INTERVENTIONNOVARTIS BETS RS 1,250 CRORE ON PFIZER'S MINIPRESS BRAND IN INDIAWHY INDIA NEEDS GLOBAL REGULATORY STANDARDS TO ATTRACT PHARMAIndia's peptide API race heats up as HRV Pharma commits Rs 150 crore to secure critical capacity in synthetic peptides.The Hyderabad-based company moves decisively into two of the most supply-constrained and high-value segments of the global pharmaceutical supply chain. POObesity drug market swings between big wins and bigger doubts as the latest updates reveal both striking advances and stubborn limits.Patients, doctors and investors watch every trial result and sales figure. These GLP-1 medicines reshape diabetes care, reduce cardiovascular risk for millions, and drive enormous revenue for companies. POChronic care and GLP-1 therapeutics reshape the Indian Pharmaceutical Market as demand shifts decisively toward long-term therapies.Lifestyle diseases drive sticky revenues while acute care faces margin pressure. Indian drugmakers actively chase cardiovascular, oncology, and anti-diabetes portfolios. POThe Centre's HPV vaccination drive comes under close watch as public interest litigation seeks Supreme Court intervention over informed consent, safety protocols, and accountability.A petition filed by the Universal Health Organization challenges the government-backed human papillomavirus vaccination program, arguing that it violates the constitutional rights of parents and minor children. PONovartis India has approved a Rs 1,250 crore deal to acquire Pfizer's Minipress and Minipress trademarks in India. The deal also includes certain related intellectual property rights.The company's board approved the transaction on September 7, 2026. Novartis India also signed an asset purchase agreement with Pfizer Inc. and Pfizer Products Inc. POIndia's pharma industry is looking beyond generics, but regulatory standards could determine how quickly it attracts global investment in innovation.Commerce and Industry Minister Piyush Goyal has called for greater alignment with developed markets to make India more attractive for research, clinical trials, and new drug development. PO
< Page 7 | Page 9 >